TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05693597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imtenan Oil
Description: Cold Press Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baraka Capsules
Description: Soft Gelatin Capsules
Study: NCT05620225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axon Therapy and CMM
Description: transcutaneous magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham and CMM
Description: Sham and CMM
Study: NCT05312697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human anti-sclerostin monoclonal antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human anti-sclerostin monoclonal antibody (mAb)
Study: NCT05830617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS
Description: The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
Study: NCT04915950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
Study: NCT05948865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO301
Description: Administered by intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO301
Description: Administered by intravenous injection
Study: NCT05423860

Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study

Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study

Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study

Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study

Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study
Study: NCT06316999

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Intestinal Ultrasound
Description: Transabdominal and trans perineal ultrasound of the pouch
Study: NCT06088602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
Study: NCT04858464

Intervention type: OTHER
Intervention: Survey study
Description: Patients will complete the mentioned questionnaires.
Study: NCT05732389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
Study: NCT04672707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 32 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 48 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 64 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 80mg
Study: NCT05120921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Treatment
Description: includes touch, joint manipulations, stretching and massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Treatment
Description: includes touch, joint manipulations, stretching and massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: Providing rehabilitative exercises to patients to do at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: Providing rehabilitative exercises to patients to do at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reassurance
Description: Reassuring patients on their symptoms, diagnosis and prognosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reassurance
Description: Reassuring patients on their symptoms, diagnosis and prognosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial management
Description: Giving a central place to the patient in the decision-making to help them to get back to valued activities.
Study: NCT05168501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebreathing procedure
Description: Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
Study: NCT05622409

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Study: NCT05690659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercise
Description: cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercise
Description: cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercise
Description: cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
Study: NCT05246865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral androgen challenge with dehydroepiandrosterone (DHEA)
Description: The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral androgen challenge with dehydroepiandrosterone (DHEA)
Description: The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
Study: NCT05607628

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Animal Protein Meals
Description: Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Plant Protein Meals
Description: Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
Study: NCT05253001

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: smartphone
Description: Use the mobile chatbot approach for intervention groups to improve prenatal education.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Description: Use the mobile chatbot approach for intervention groups to improve prenatal education.
Study: NCT04548843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow mobilization
Description: During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNV-BM-PLC infusion
Description: The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks.
Study: NCT05705635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for injection (Albumin-bound)
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Taxotere, by intravenous infusion, every 3 weeks.
Study: NCT04638244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Brief Online Music

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading messages
Description: Reading psychoeducational messages
Study: NCT05289401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided blocks
Description: Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided blocks
Description: Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
Study: NCT05659537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study: NCT05561205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate
Study: NCT05787600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhyal rinse
Description: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study: NCT05254145

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
Study: NCT05583513

Intervention type: DIAGNOSTIC_TEST
Intervention: MLHFQ (Minnesota Living with Heart Failure Questionnaire)
Description: The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL

Intervention type: DIAGNOSTIC_TEST
Intervention: KCCQ (the Kansas City Cardiomyopathy Questionnaire)
Description: The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
Study: NCT06492499

Intervention type: PROCEDURE
Intervention: Zero-Fluoroscopy Radiofrequency Catheter Ablation
Description: Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
Study: NCT05922670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth
Description: BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
Study: NCT06298942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural band
Description: to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silicone band
Description: to use synesthetic band with sleeve gastrectomy
Study: NCT05014737

Intervention type: OTHER
Intervention: no intervention
Description: this is an abservational study and no intervention will be involved
Study: NCT05525598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One step at a time
Description: \[see 'arms' section for full description\]

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get started
Description: \[see 'arms' section for full description\]
Study: NCT05784285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in a 8-week community-based activity program
Description: Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
Study: NCT04901962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOBST® Confidence compression garments
Description: JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
Study: NCT06083389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kabat technique for rehabilitation of facial palsy
Description: To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrotherapy
Description: electrical stimulation of facial nerve supplied muscles.3 sessions per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrotherapy
Description: electrical stimulation of facial nerve supplied muscles.3 sessions per week.
Study: NCT04810689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuanfei Baidu Granules
Description: Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
Study: NCT06433674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
Study: NCT04955600

Intervention type: OTHER
Intervention: Implementation Study
Description: Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
Study: NCT04754217

Intervention type: DEVICE
Intervention: VAVGJ
Description: Replacement of the aortic valve and ascending aorta

Intervention type: DEVICE
Intervention: CAVGJ
Description: Replacement of the aortic valve and ascending aorta